Background
Results
Pathogens and morbidity
Serology test | Range of test | Median (IQR) | Total | DM+ | CVD+ | Frail+ |
---|---|---|---|---|---|---|
(U/ml) | Titer (U/ml) | number(%) | (n = 59) | (n = 143) | (n = 131) | |
HSV
a
IgG positive
| 30-2000 | 437 (389–484) | 275 (93%) | 57 (97%) | 133 (93%) | 122 (93%) |
HSV
a
IgG negative
| - | 20 (7%) | 2 (3%) | 10 (7%) | 9 (7%) | |
VZV
a
IgG positive
| 100-2000 | 994 (612–1403) | 292 (99%) | 59 (100%) | 141 (99%) | 128 (98%) |
VZV
a
IgG negative
| - | 3 (1%) | 0 (0%) | 2 (1%) | 3 (2%) | |
EBV
a
IgG positive
| 11-200 | 200 (130–200) | 291 (99)% | 58 (98%) | 141 (99%) | 128 (98%) |
EBV
a
IgG negative
| - | 4 (1%) | 1 (2%) | 2 (1%) | 3 (2%) | |
CMV
a
IgG positive
| 226 (77%) | 46 (78%) | 115 (80%) | 108 (82%)b | ||
• AxSYM | 15-250 | 250 (192–250) | ||||
• DSX
TM
| 40-2000 | 373 (290–463) | ||||
CMV
a
IgG negative
| - | 69 (23%) | 13 (22%) | 28 (20%) | 23 (18%)b | |
HHV6
a
IgG positive
| >1.1 | 1.67 (1.37-2.34) | 193 (65%) | 45 (76%)c | 97 (68%) | 90 (69%) |
HHV6
a
IgG negative
|
-
| 102 (35%) | 14 (24%)c | 46 (32%) | 41 (31%) | |
CP
a
IgG positive
| 45-270 | 81 (59–116) | 150 (51%) | 28 (47%) | 74 (52%) | 68 (52%) |
CP
a
IgG negative
| - | 144 (49%) | 31 (53%) | 69 (48%) | 63 (48%) | |
HP
a
IgG positive
| 20-650 | 97 (36–211) | 173 (59%) | 32 (54%) | 82 (47%) | 77 (59%) |
HP
a
IgG negative
| - | 121 (41%) | 27 (46%) | 61 (43%) | 54 (41%) | |
Pathogen burden
d
| - | |||||
● Pathogen burden ≤ 4
| 53 (18%) | 9 (15%) | 25 (18%) | 18 (14%) | ||
● Pathogen burden = 5
| - | 95 (32%) | 18 (31%) | 46 (32%) | 44 (33%) | |
● Pathogen burden = 6
| - | 103 (35%) | 23 (39%) | 46 (32%) | 48 (37%) | |
● Pathogen burden = 7
| - | 44 (15%) | 9 (15%) | 26 (18%) | 21 (16%) |
Test | CMV result | N | Frailty + | Frailty – | RR (95% CI) |
---|---|---|---|---|---|
(n = 131) | (n = 164) | ||||
AxSYM
| CMV titer: <15 AU/ml | 69 | 23 (17.5%) | 46 (28.4%) | |
CMV titer: 15–192 AU/ml | 55 | 22 (17.0%) | 33 (20.4%) | 1.2 (0.71-2.00) | |
CMV titer: ≥192 AU/ml | 169 | 86 (65.5%) | 83 (51.2%) | 1.5 (1.06-2.30) | |
DSX
™
| CMV titer: <40 U/ml | 67 | 22 (16.8%) | 45 (27.44%) | |
CMV titer: 40–290 U/ml | 56 | 22 (16.8%) | 34 (20.73%) | 1.2 (0.72-2.03) | |
CMV titer: ≥290 U/ml | 172 | 87 (66.4%) | 85 (51.83%) | 1.5 (1.06-2.35) |
Test result | N | DM + | DM – | RR ratio (95% CI) |
---|---|---|---|---|
(n = 59) | (n = 236) | |||
HHV6
| ||||
• HHV6 titer: <1.1 | 103 | 14 (23.7%) | 89 (37.7%) | |
• HHV6 titer: 1.1-2.3 | 144 | 27 (45.8%) | 117 (49.6%) | 1.38 (0.74-2.66) |
• HHV6 titer: >2.3 | 48 | 18 (30.5%) | 30 (12.7%) | 2.76 (1.42-5.36) |
EBV
| ||||
• EBV titer: 0–200 U/ml | 144 | 21 (35.6%) | 123 (52.1%) | |
• EBV titer: ≥200 U/ml | 151 | 38 (64.4%) | 113 (47.9%) | 1.73 (1.04-2.91) |
HHV6 and EBV
| ||||
• HHV6 titer <1.1 and EBV titer 0-200 | 127 | 15 (25.4%) | 112 (47.5%) | |
• HHV6 titer 1.1-2.3 and EBV titer > =200 or HHV6 titer >2.3 and EBV titer 0-200 | 137 | 32 (54.2%) | 105 (44.5%) | 2.28 (1.1-4.7) |
• HHV6 titer >2.3 and EBV titer > =200 | 31 | 12 (20.4%) | 19 (8.0%) | 3.28 (1.57-6.49) |
Pathogens and mortality
Unadjusted RR (95% CI) | Adjusted for frailty RR (95% CI) | |
---|---|---|
HSV
a
| 1.23 (0.38-3.93) | 1.24 (0.39-3.96) |
CMV
b
| 1.60 (0.81-3.15) | 1.20 (0.61-2.39) |
HHV6
c
| 1.00 (0.59-1.71) | 0.88 (0.5-1.49) |
CP
d
| 1.07 (0.64-1.77) | 1.06 (0.64-1.76) |
HP
e
| 1.26 (0.75-2.13) | 1.24 (0.73-2.09) |